nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—MAP2K1—lung cancer	0.539	1	CbGaD
Trametinib—CYP2C8—Erlotinib—lung cancer	0.0198	0.126	CbGbCtD
Trametinib—CYP2C8—Paclitaxel—lung cancer	0.0181	0.116	CbGbCtD
Trametinib—CYP3A4—Topotecan—lung cancer	0.0149	0.0947	CbGbCtD
Trametinib—CYP2C8—Etoposide—lung cancer	0.0143	0.0913	CbGbCtD
Trametinib—CYP3A4—Gefitinib—lung cancer	0.0136	0.0866	CbGbCtD
Trametinib—CYP3A4—Teniposide—lung cancer	0.0132	0.084	CbGbCtD
Trametinib—CYP3A4—Vinorelbine—lung cancer	0.0105	0.0667	CbGbCtD
Trametinib—CYP3A4—Crizotinib—lung cancer	0.00833	0.0531	CbGbCtD
Trametinib—CYP3A4—Erlotinib—lung cancer	0.00803	0.0512	CbGbCtD
Trametinib—CYP3A4—Paclitaxel—lung cancer	0.00735	0.0469	CbGbCtD
Trametinib—CYP3A4—Irinotecan—lung cancer	0.00725	0.0462	CbGbCtD
Trametinib—CYP3A4—Vinblastine—lung cancer	0.00645	0.0411	CbGbCtD
Trametinib—CYP3A4—Etoposide—lung cancer	0.00581	0.037	CbGbCtD
Trametinib—CYP3A4—Docetaxel—lung cancer	0.00532	0.0339	CbGbCtD
Trametinib—CYP3A4—Doxorubicin—lung cancer	0.00396	0.0253	CbGbCtD
Trametinib—MAP2K1—respiratory system—lung cancer	0.0019	0.137	CbGeAlD
Trametinib—MAP2K2—respiratory system—lung cancer	0.00167	0.121	CbGeAlD
Trametinib—MAP2K1—epithelium—lung cancer	0.00158	0.115	CbGeAlD
Trametinib—MAP2K2—bronchus—lung cancer	0.00137	0.0994	CbGeAlD
Trametinib—MAP2K2—cardiac atrium—lung cancer	0.00116	0.0838	CbGeAlD
Trametinib—MAP2K1—bone marrow—lung cancer	0.00111	0.0804	CbGeAlD
Trametinib—MAP2K1—lung—lung cancer	0.00101	0.0728	CbGeAlD
Trametinib—MAP2K2—bone marrow—lung cancer	0.000979	0.0708	CbGeAlD
Trametinib—MAP2K2—lung—lung cancer	0.000887	0.0641	CbGeAlD
Trametinib—CYP2C8—mammary gland—lung cancer	0.000868	0.0627	CbGeAlD
Trametinib—MAP2K1—lymph node—lung cancer	0.000689	0.0498	CbGeAlD
Trametinib—MAP2K2—lymph node—lung cancer	0.000606	0.0438	CbGeAlD
Trametinib—Pruritus—Vinorelbine—lung cancer	6.52e-05	0.00047	CcSEcCtD
Trametinib—Constipation—Irinotecan—lung cancer	6.5e-05	0.000469	CcSEcCtD
Trametinib—Mental disorder—Docetaxel—lung cancer	6.48e-05	0.000467	CcSEcCtD
Trametinib—Myalgia—Paclitaxel—lung cancer	6.46e-05	0.000466	CcSEcCtD
Trametinib—Arthralgia—Paclitaxel—lung cancer	6.46e-05	0.000466	CcSEcCtD
Trametinib—Malnutrition—Docetaxel—lung cancer	6.44e-05	0.000464	CcSEcCtD
Trametinib—Erythema—Docetaxel—lung cancer	6.44e-05	0.000464	CcSEcCtD
Trametinib—Decreased appetite—Gemcitabine—lung cancer	6.43e-05	0.000464	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	6.42e-05	0.000463	CcSEcCtD
Trametinib—Nausea—Topotecan—lung cancer	6.4e-05	0.000461	CcSEcCtD
Trametinib—Gastrointestinal disorder—Gemcitabine—lung cancer	6.39e-05	0.000461	CcSEcCtD
Trametinib—Abdominal discomfort—Methotrexate—lung cancer	6.38e-05	0.00046	CcSEcCtD
Trametinib—Fatigue—Gemcitabine—lung cancer	6.38e-05	0.00046	CcSEcCtD
Trametinib—Constipation—Gemcitabine—lung cancer	6.33e-05	0.000456	CcSEcCtD
Trametinib—Nausea—Erlotinib—lung cancer	6.33e-05	0.000456	CcSEcCtD
Trametinib—Dry mouth—Paclitaxel—lung cancer	6.32e-05	0.000456	CcSEcCtD
Trametinib—Diarrhoea—Vinorelbine—lung cancer	6.3e-05	0.000455	CcSEcCtD
Trametinib—Dysgeusia—Docetaxel—lung cancer	6.3e-05	0.000454	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Cisplatin—lung cancer	6.29e-05	0.000453	CcSEcCtD
Trametinib—Infection—Etoposide—lung cancer	6.28e-05	0.000453	CcSEcCtD
Trametinib—Blood creatinine increased—Doxorubicin—lung cancer	6.25e-05	0.000451	CcSEcCtD
Trametinib—Back pain—Docetaxel—lung cancer	6.23e-05	0.000449	CcSEcCtD
Trametinib—Neutropenia—Methotrexate—lung cancer	6.23e-05	0.000449	CcSEcCtD
Trametinib—Gastrointestinal pain—Irinotecan—lung cancer	6.21e-05	0.000448	CcSEcCtD
Trametinib—Dehydration—Doxorubicin—lung cancer	6.2e-05	0.000447	CcSEcCtD
Trametinib—Oedema—Paclitaxel—lung cancer	6.2e-05	0.000447	CcSEcCtD
Trametinib—Thrombocytopenia—Etoposide—lung cancer	6.19e-05	0.000446	CcSEcCtD
Trametinib—Muscle spasms—Docetaxel—lung cancer	6.19e-05	0.000446	CcSEcCtD
Trametinib—Infection—Paclitaxel—lung cancer	6.16e-05	0.000444	CcSEcCtD
Trametinib—Skin disorder—Etoposide—lung cancer	6.14e-05	0.000443	CcSEcCtD
Trametinib—Dry skin—Doxorubicin—lung cancer	6.11e-05	0.000441	CcSEcCtD
Trametinib—Hyperhidrosis—Etoposide—lung cancer	6.11e-05	0.000441	CcSEcCtD
Trametinib—Dizziness—Vinorelbine—lung cancer	6.09e-05	0.000439	CcSEcCtD
Trametinib—Abdominal pain upper—Doxorubicin—lung cancer	6.09e-05	0.000439	CcSEcCtD
Trametinib—Nervous system disorder—Paclitaxel—lung cancer	6.08e-05	0.000438	CcSEcCtD
Trametinib—Hypokalaemia—Doxorubicin—lung cancer	6.07e-05	0.000438	CcSEcCtD
Trametinib—Thrombocytopenia—Paclitaxel—lung cancer	6.07e-05	0.000438	CcSEcCtD
Trametinib—Skin disorder—Paclitaxel—lung cancer	6.02e-05	0.000434	CcSEcCtD
Trametinib—Body temperature increased—Irinotecan—lung cancer	6.01e-05	0.000433	CcSEcCtD
Trametinib—Abdominal pain—Irinotecan—lung cancer	6.01e-05	0.000433	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Doxorubicin—lung cancer	6.01e-05	0.000433	CcSEcCtD
Trametinib—Decreased appetite—Cisplatin—lung cancer	6e-05	0.000432	CcSEcCtD
Trametinib—Hyperhidrosis—Paclitaxel—lung cancer	5.99e-05	0.000432	CcSEcCtD
Trametinib—Gastrointestinal disorder—Cisplatin—lung cancer	5.96e-05	0.00043	CcSEcCtD
Trametinib—Anaemia—Docetaxel—lung cancer	5.95e-05	0.000429	CcSEcCtD
Trametinib—Infestation NOS—Methotrexate—lung cancer	5.94e-05	0.000428	CcSEcCtD
Trametinib—Infestation—Methotrexate—lung cancer	5.94e-05	0.000428	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Doxorubicin—lung cancer	5.88e-05	0.000424	CcSEcCtD
Trametinib—Vomiting—Vinorelbine—lung cancer	5.86e-05	0.000422	CcSEcCtD
Trametinib—Body temperature increased—Gemcitabine—lung cancer	5.85e-05	0.000422	CcSEcCtD
Trametinib—Renal failure—Methotrexate—lung cancer	5.84e-05	0.000421	CcSEcCtD
Trametinib—Rash—Vinorelbine—lung cancer	5.81e-05	0.000419	CcSEcCtD
Trametinib—Dermatitis—Vinorelbine—lung cancer	5.8e-05	0.000419	CcSEcCtD
Trametinib—Stomatitis—Methotrexate—lung cancer	5.79e-05	0.000417	CcSEcCtD
Trametinib—Headache—Vinorelbine—lung cancer	5.77e-05	0.000416	CcSEcCtD
Trametinib—Leukopenia—Docetaxel—lung cancer	5.76e-05	0.000415	CcSEcCtD
Trametinib—Haematuria—Methotrexate—lung cancer	5.66e-05	0.000408	CcSEcCtD
Trametinib—Pancreatitis—Doxorubicin—lung cancer	5.65e-05	0.000408	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Paclitaxel—lung cancer	5.65e-05	0.000407	CcSEcCtD
Trametinib—Cough—Docetaxel—lung cancer	5.62e-05	0.000405	CcSEcCtD
Trametinib—Insomnia—Paclitaxel—lung cancer	5.61e-05	0.000404	CcSEcCtD
Trametinib—Epistaxis—Methotrexate—lung cancer	5.6e-05	0.000404	CcSEcCtD
Trametinib—Hypertension—Docetaxel—lung cancer	5.56e-05	0.000401	CcSEcCtD
Trametinib—Decreased appetite—Etoposide—lung cancer	5.49e-05	0.000396	CcSEcCtD
Trametinib—Arthralgia—Docetaxel—lung cancer	5.48e-05	0.000395	CcSEcCtD
Trametinib—Myalgia—Docetaxel—lung cancer	5.48e-05	0.000395	CcSEcCtD
Trametinib—Nausea—Vinorelbine—lung cancer	5.47e-05	0.000395	CcSEcCtD
Trametinib—Gastrointestinal disorder—Etoposide—lung cancer	5.46e-05	0.000393	CcSEcCtD
Trametinib—Body temperature increased—Cisplatin—lung cancer	5.45e-05	0.000393	CcSEcCtD
Trametinib—Asthenia—Irinotecan—lung cancer	5.45e-05	0.000393	CcSEcCtD
Trametinib—Fatigue—Etoposide—lung cancer	5.45e-05	0.000393	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	5.44e-05	0.000392	CcSEcCtD
Trametinib—Constipation—Etoposide—lung cancer	5.41e-05	0.00039	CcSEcCtD
Trametinib—Neutropenia—Doxorubicin—lung cancer	5.39e-05	0.000389	CcSEcCtD
Trametinib—Decreased appetite—Paclitaxel—lung cancer	5.39e-05	0.000388	CcSEcCtD
Trametinib—Dry mouth—Docetaxel—lung cancer	5.36e-05	0.000386	CcSEcCtD
Trametinib—Haemoglobin—Methotrexate—lung cancer	5.36e-05	0.000386	CcSEcCtD
Trametinib—Gastrointestinal disorder—Paclitaxel—lung cancer	5.35e-05	0.000386	CcSEcCtD
Trametinib—Fatigue—Paclitaxel—lung cancer	5.34e-05	0.000385	CcSEcCtD
Trametinib—Haemorrhage—Methotrexate—lung cancer	5.33e-05	0.000384	CcSEcCtD
Trametinib—Asthenia—Gemcitabine—lung cancer	5.31e-05	0.000383	CcSEcCtD
Trametinib—Constipation—Paclitaxel—lung cancer	5.3e-05	0.000382	CcSEcCtD
Trametinib—Urinary tract disorder—Methotrexate—lung cancer	5.26e-05	0.000379	CcSEcCtD
Trametinib—Oedema—Docetaxel—lung cancer	5.25e-05	0.000379	CcSEcCtD
Trametinib—Pruritus—Gemcitabine—lung cancer	5.24e-05	0.000378	CcSEcCtD
Trametinib—Urethral disorder—Methotrexate—lung cancer	5.22e-05	0.000377	CcSEcCtD
Trametinib—Infection—Docetaxel—lung cancer	5.22e-05	0.000376	CcSEcCtD
Trametinib—Hyperglycaemia—Doxorubicin—lung cancer	5.2e-05	0.000375	CcSEcCtD
Trametinib—Diarrhoea—Irinotecan—lung cancer	5.2e-05	0.000375	CcSEcCtD
Trametinib—Gastrointestinal pain—Etoposide—lung cancer	5.17e-05	0.000373	CcSEcCtD
Trametinib—Nervous system disorder—Docetaxel—lung cancer	5.15e-05	0.000371	CcSEcCtD
Trametinib—Thrombocytopenia—Docetaxel—lung cancer	5.14e-05	0.000371	CcSEcCtD
Trametinib—Infestation NOS—Doxorubicin—lung cancer	5.14e-05	0.000371	CcSEcCtD
Trametinib—Infestation—Doxorubicin—lung cancer	5.14e-05	0.000371	CcSEcCtD
Trametinib—Skin disorder—Docetaxel—lung cancer	5.1e-05	0.000368	CcSEcCtD
Trametinib—Gastrointestinal pain—Paclitaxel—lung cancer	5.07e-05	0.000365	CcSEcCtD
Trametinib—Diarrhoea—Gemcitabine—lung cancer	5.06e-05	0.000365	CcSEcCtD
Trametinib—Renal failure—Doxorubicin—lung cancer	5.05e-05	0.000364	CcSEcCtD
Trametinib—Dizziness—Irinotecan—lung cancer	5.02e-05	0.000362	CcSEcCtD
Trametinib—Stomatitis—Doxorubicin—lung cancer	5.01e-05	0.000361	CcSEcCtD
Trametinib—Abdominal pain—Etoposide—lung cancer	5e-05	0.00036	CcSEcCtD
Trametinib—Body temperature increased—Etoposide—lung cancer	5e-05	0.00036	CcSEcCtD
Trametinib—Urinary tract infection—Doxorubicin—lung cancer	5e-05	0.00036	CcSEcCtD
Trametinib—Eye disorder—Methotrexate—lung cancer	4.98e-05	0.000359	CcSEcCtD
Trametinib—Asthenia—Cisplatin—lung cancer	4.95e-05	0.000357	CcSEcCtD
Trametinib—Cardiac disorder—Methotrexate—lung cancer	4.95e-05	0.000357	CcSEcCtD
Trametinib—Haematuria—Doxorubicin—lung cancer	4.9e-05	0.000353	CcSEcCtD
Trametinib—Abdominal pain—Paclitaxel—lung cancer	4.9e-05	0.000353	CcSEcCtD
Trametinib—Body temperature increased—Paclitaxel—lung cancer	4.9e-05	0.000353	CcSEcCtD
Trametinib—Epistaxis—Doxorubicin—lung cancer	4.85e-05	0.00035	CcSEcCtD
Trametinib—Angiopathy—Methotrexate—lung cancer	4.83e-05	0.000349	CcSEcCtD
Trametinib—Vomiting—Irinotecan—lung cancer	4.83e-05	0.000348	CcSEcCtD
Trametinib—Mediastinal disorder—Methotrexate—lung cancer	4.8e-05	0.000346	CcSEcCtD
Trametinib—Rash—Irinotecan—lung cancer	4.79e-05	0.000345	CcSEcCtD
Trametinib—Dermatitis—Irinotecan—lung cancer	4.79e-05	0.000345	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Docetaxel—lung cancer	4.79e-05	0.000345	CcSEcCtD
Trametinib—Chills—Methotrexate—lung cancer	4.78e-05	0.000345	CcSEcCtD
Trametinib—Headache—Irinotecan—lung cancer	4.76e-05	0.000343	CcSEcCtD
Trametinib—Insomnia—Docetaxel—lung cancer	4.75e-05	0.000343	CcSEcCtD
Trametinib—Diarrhoea—Cisplatin—lung cancer	4.72e-05	0.00034	CcSEcCtD
Trametinib—Vomiting—Gemcitabine—lung cancer	4.71e-05	0.000339	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—lung cancer	4.7e-05	0.000339	CcSEcCtD
Trametinib—Mental disorder—Methotrexate—lung cancer	4.67e-05	0.000337	CcSEcCtD
Trametinib—Rash—Gemcitabine—lung cancer	4.67e-05	0.000337	CcSEcCtD
Trametinib—Dermatitis—Gemcitabine—lung cancer	4.66e-05	0.000336	CcSEcCtD
Trametinib—Malnutrition—Methotrexate—lung cancer	4.64e-05	0.000335	CcSEcCtD
Trametinib—Erythema—Methotrexate—lung cancer	4.64e-05	0.000335	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—lung cancer	4.64e-05	0.000334	CcSEcCtD
Trametinib—Headache—Gemcitabine—lung cancer	4.64e-05	0.000334	CcSEcCtD
Trametinib—Haemorrhage—Doxorubicin—lung cancer	4.61e-05	0.000333	CcSEcCtD
Trametinib—Decreased appetite—Docetaxel—lung cancer	4.57e-05	0.000329	CcSEcCtD
Trametinib—Urinary tract disorder—Doxorubicin—lung cancer	4.56e-05	0.000329	CcSEcCtD
Trametinib—Oedema peripheral—Doxorubicin—lung cancer	4.55e-05	0.000328	CcSEcCtD
Trametinib—Dysgeusia—Methotrexate—lung cancer	4.54e-05	0.000328	CcSEcCtD
Trametinib—Gastrointestinal disorder—Docetaxel—lung cancer	4.53e-05	0.000327	CcSEcCtD
Trametinib—Asthenia—Etoposide—lung cancer	4.53e-05	0.000327	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—lung cancer	4.53e-05	0.000327	CcSEcCtD
Trametinib—Fatigue—Docetaxel—lung cancer	4.53e-05	0.000327	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—lung cancer	4.52e-05	0.000326	CcSEcCtD
Trametinib—Nausea—Irinotecan—lung cancer	4.51e-05	0.000325	CcSEcCtD
Trametinib—Constipation—Docetaxel—lung cancer	4.49e-05	0.000324	CcSEcCtD
Trametinib—Back pain—Methotrexate—lung cancer	4.49e-05	0.000324	CcSEcCtD
Trametinib—Pruritus—Etoposide—lung cancer	4.47e-05	0.000322	CcSEcCtD
Trametinib—Asthenia—Paclitaxel—lung cancer	4.45e-05	0.000321	CcSEcCtD
Trametinib—Nausea—Gemcitabine—lung cancer	4.4e-05	0.000317	CcSEcCtD
Trametinib—Vomiting—Cisplatin—lung cancer	4.39e-05	0.000316	CcSEcCtD
Trametinib—Pruritus—Paclitaxel—lung cancer	4.38e-05	0.000316	CcSEcCtD
Trametinib—Vision blurred—Methotrexate—lung cancer	4.37e-05	0.000315	CcSEcCtD
Trametinib—Rash—Cisplatin—lung cancer	4.35e-05	0.000314	CcSEcCtD
Trametinib—Dermatitis—Cisplatin—lung cancer	4.35e-05	0.000313	CcSEcCtD
Trametinib—Diarrhoea—Etoposide—lung cancer	4.32e-05	0.000312	CcSEcCtD
Trametinib—Eye disorder—Doxorubicin—lung cancer	4.31e-05	0.000311	CcSEcCtD
Trametinib—Gastrointestinal pain—Docetaxel—lung cancer	4.3e-05	0.00031	CcSEcCtD
Trametinib—Anaemia—Methotrexate—lung cancer	4.29e-05	0.000309	CcSEcCtD
Trametinib—Cardiac disorder—Doxorubicin—lung cancer	4.28e-05	0.000309	CcSEcCtD
Trametinib—Diarrhoea—Paclitaxel—lung cancer	4.24e-05	0.000306	CcSEcCtD
Trametinib—Angiopathy—Doxorubicin—lung cancer	4.19e-05	0.000302	CcSEcCtD
Trametinib—Dizziness—Etoposide—lung cancer	4.18e-05	0.000301	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—lung cancer	4.16e-05	0.0003	CcSEcCtD
Trametinib—Abdominal pain—Docetaxel—lung cancer	4.15e-05	0.000299	CcSEcCtD
Trametinib—Body temperature increased—Docetaxel—lung cancer	4.15e-05	0.000299	CcSEcCtD
Trametinib—Leukopenia—Methotrexate—lung cancer	4.15e-05	0.000299	CcSEcCtD
Trametinib—Chills—Doxorubicin—lung cancer	4.14e-05	0.000299	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—lung cancer	4.12e-05	0.000297	CcSEcCtD
Trametinib—Dizziness—Paclitaxel—lung cancer	4.1e-05	0.000296	CcSEcCtD
Trametinib—Nausea—Cisplatin—lung cancer	4.1e-05	0.000296	CcSEcCtD
Trametinib—Cough—Methotrexate—lung cancer	4.05e-05	0.000292	CcSEcCtD
Trametinib—Mental disorder—Doxorubicin—lung cancer	4.04e-05	0.000292	CcSEcCtD
Trametinib—Vomiting—Etoposide—lung cancer	4.02e-05	0.00029	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—lung cancer	4.02e-05	0.00029	CcSEcCtD
Trametinib—Erythema—Doxorubicin—lung cancer	4.02e-05	0.00029	CcSEcCtD
Trametinib—Rash—Etoposide—lung cancer	3.99e-05	0.000287	CcSEcCtD
Trametinib—Dermatitis—Etoposide—lung cancer	3.98e-05	0.000287	CcSEcCtD
Trametinib—Headache—Etoposide—lung cancer	3.96e-05	0.000286	CcSEcCtD
Trametinib—Myalgia—Methotrexate—lung cancer	3.95e-05	0.000285	CcSEcCtD
Trametinib—Arthralgia—Methotrexate—lung cancer	3.95e-05	0.000285	CcSEcCtD
Trametinib—Vomiting—Paclitaxel—lung cancer	3.94e-05	0.000284	CcSEcCtD
Trametinib—Dysgeusia—Doxorubicin—lung cancer	3.93e-05	0.000284	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	3.92e-05	0.000283	CcSEcCtD
Trametinib—Rash—Paclitaxel—lung cancer	3.91e-05	0.000282	CcSEcCtD
Trametinib—Dermatitis—Paclitaxel—lung cancer	3.9e-05	0.000282	CcSEcCtD
Trametinib—Back pain—Doxorubicin—lung cancer	3.89e-05	0.00028	CcSEcCtD
Trametinib—Headache—Paclitaxel—lung cancer	3.88e-05	0.00028	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—lung cancer	3.86e-05	0.000278	CcSEcCtD
Trametinib—Vision blurred—Doxorubicin—lung cancer	3.79e-05	0.000273	CcSEcCtD
Trametinib—Asthenia—Docetaxel—lung cancer	3.77e-05	0.000272	CcSEcCtD
Trametinib—Infection—Methotrexate—lung cancer	3.76e-05	0.000271	CcSEcCtD
Trametinib—Nausea—Etoposide—lung cancer	3.75e-05	0.000271	CcSEcCtD
Trametinib—Pruritus—Docetaxel—lung cancer	3.72e-05	0.000268	CcSEcCtD
Trametinib—Nervous system disorder—Methotrexate—lung cancer	3.71e-05	0.000268	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—lung cancer	3.71e-05	0.000268	CcSEcCtD
Trametinib—Thrombocytopenia—Methotrexate—lung cancer	3.71e-05	0.000267	CcSEcCtD
Trametinib—Nausea—Paclitaxel—lung cancer	3.68e-05	0.000265	CcSEcCtD
Trametinib—Skin disorder—Methotrexate—lung cancer	3.68e-05	0.000265	CcSEcCtD
Trametinib—Hyperhidrosis—Methotrexate—lung cancer	3.66e-05	0.000264	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—lung cancer	3.6e-05	0.000259	CcSEcCtD
Trametinib—Diarrhoea—Docetaxel—lung cancer	3.59e-05	0.000259	CcSEcCtD
Trametinib—Cough—Doxorubicin—lung cancer	3.51e-05	0.000253	CcSEcCtD
Trametinib—Dizziness—Docetaxel—lung cancer	3.47e-05	0.00025	CcSEcCtD
Trametinib—Hypertension—Doxorubicin—lung cancer	3.47e-05	0.00025	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Methotrexate—lung cancer	3.45e-05	0.000249	CcSEcCtD
Trametinib—Insomnia—Methotrexate—lung cancer	3.42e-05	0.000247	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—lung cancer	3.42e-05	0.000247	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—lung cancer	3.42e-05	0.000247	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	3.4e-05	0.000245	CcSEcCtD
Trametinib—Dry mouth—Doxorubicin—lung cancer	3.34e-05	0.000241	CcSEcCtD
Trametinib—Vomiting—Docetaxel—lung cancer	3.34e-05	0.000241	CcSEcCtD
Trametinib—Rash—Docetaxel—lung cancer	3.31e-05	0.000239	CcSEcCtD
Trametinib—Dermatitis—Docetaxel—lung cancer	3.31e-05	0.000239	CcSEcCtD
Trametinib—Decreased appetite—Methotrexate—lung cancer	3.29e-05	0.000237	CcSEcCtD
Trametinib—Headache—Docetaxel—lung cancer	3.29e-05	0.000237	CcSEcCtD
Trametinib—Oedema—Doxorubicin—lung cancer	3.28e-05	0.000236	CcSEcCtD
Trametinib—Gastrointestinal disorder—Methotrexate—lung cancer	3.27e-05	0.000236	CcSEcCtD
Trametinib—Fatigue—Methotrexate—lung cancer	3.26e-05	0.000235	CcSEcCtD
Trametinib—Infection—Doxorubicin—lung cancer	3.26e-05	0.000235	CcSEcCtD
Trametinib—Nervous system disorder—Doxorubicin—lung cancer	3.21e-05	0.000232	CcSEcCtD
Trametinib—Thrombocytopenia—Doxorubicin—lung cancer	3.21e-05	0.000231	CcSEcCtD
Trametinib—Skin disorder—Doxorubicin—lung cancer	3.18e-05	0.00023	CcSEcCtD
Trametinib—Hyperhidrosis—Doxorubicin—lung cancer	3.17e-05	0.000229	CcSEcCtD
Trametinib—Nausea—Docetaxel—lung cancer	3.12e-05	0.000225	CcSEcCtD
Trametinib—Gastrointestinal pain—Methotrexate—lung cancer	3.1e-05	0.000223	CcSEcCtD
Trametinib—Body temperature increased—Methotrexate—lung cancer	2.99e-05	0.000216	CcSEcCtD
Trametinib—Abdominal pain—Methotrexate—lung cancer	2.99e-05	0.000216	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—lung cancer	2.99e-05	0.000215	CcSEcCtD
Trametinib—Insomnia—Doxorubicin—lung cancer	2.97e-05	0.000214	CcSEcCtD
Trametinib—Decreased appetite—Doxorubicin—lung cancer	2.85e-05	0.000205	CcSEcCtD
Trametinib—Gastrointestinal disorder—Doxorubicin—lung cancer	2.83e-05	0.000204	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—lung cancer	2.83e-05	0.000204	CcSEcCtD
Trametinib—Constipation—Doxorubicin—lung cancer	2.8e-05	0.000202	CcSEcCtD
Trametinib—Asthenia—Methotrexate—lung cancer	2.72e-05	0.000196	CcSEcCtD
Trametinib—Gastrointestinal pain—Doxorubicin—lung cancer	2.68e-05	0.000193	CcSEcCtD
Trametinib—Pruritus—Methotrexate—lung cancer	2.68e-05	0.000193	CcSEcCtD
Trametinib—Abdominal pain—Doxorubicin—lung cancer	2.59e-05	0.000187	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—lung cancer	2.59e-05	0.000187	CcSEcCtD
Trametinib—Diarrhoea—Methotrexate—lung cancer	2.59e-05	0.000187	CcSEcCtD
Trametinib—Dizziness—Methotrexate—lung cancer	2.5e-05	0.000181	CcSEcCtD
Trametinib—Vomiting—Methotrexate—lung cancer	2.41e-05	0.000174	CcSEcCtD
Trametinib—Rash—Methotrexate—lung cancer	2.39e-05	0.000172	CcSEcCtD
Trametinib—Dermatitis—Methotrexate—lung cancer	2.38e-05	0.000172	CcSEcCtD
Trametinib—Headache—Methotrexate—lung cancer	2.37e-05	0.000171	CcSEcCtD
Trametinib—Asthenia—Doxorubicin—lung cancer	2.35e-05	0.00017	CcSEcCtD
Trametinib—Pruritus—Doxorubicin—lung cancer	2.32e-05	0.000167	CcSEcCtD
Trametinib—Nausea—Methotrexate—lung cancer	2.25e-05	0.000162	CcSEcCtD
Trametinib—Diarrhoea—Doxorubicin—lung cancer	2.24e-05	0.000162	CcSEcCtD
Trametinib—Dizziness—Doxorubicin—lung cancer	2.17e-05	0.000156	CcSEcCtD
Trametinib—Vomiting—Doxorubicin—lung cancer	2.08e-05	0.00015	CcSEcCtD
Trametinib—Rash—Doxorubicin—lung cancer	2.07e-05	0.000149	CcSEcCtD
Trametinib—Dermatitis—Doxorubicin—lung cancer	2.07e-05	0.000149	CcSEcCtD
Trametinib—Headache—Doxorubicin—lung cancer	2.05e-05	0.000148	CcSEcCtD
Trametinib—Nausea—Doxorubicin—lung cancer	1.95e-05	0.00014	CcSEcCtD
Trametinib—MAP2K1—Signaling by GPCR—IL2—lung cancer	4.02e-06	2.66e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	4.01e-06	2.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TERT—lung cancer	4e-06	2.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MTOR—lung cancer	4e-06	2.64e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CB—lung cancer	4e-06	2.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ERBB2—lung cancer	4e-06	2.64e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD4—lung cancer	3.99e-06	2.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IL6—lung cancer	3.96e-06	2.62e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—lung cancer	3.96e-06	2.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APOA1—lung cancer	3.95e-06	2.61e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CB—lung cancer	3.94e-06	2.61e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MTOR—lung cancer	3.94e-06	2.61e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CD4—lung cancer	3.94e-06	2.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL2—lung cancer	3.92e-06	2.59e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP2A7—lung cancer	3.92e-06	2.59e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KDR—lung cancer	3.91e-06	2.59e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTGS2—lung cancer	3.91e-06	2.58e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FGFR1—lung cancer	3.89e-06	2.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HRAS—lung cancer	3.87e-06	2.56e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—AKT1—lung cancer	3.87e-06	2.56e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SDC4—lung cancer	3.84e-06	2.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HIF1A—lung cancer	3.83e-06	2.53e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—JUN—lung cancer	3.82e-06	2.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MDM2—lung cancer	3.79e-06	2.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—RAF1—lung cancer	3.78e-06	2.5e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ERBB2—lung cancer	3.74e-06	2.47e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6—lung cancer	3.7e-06	2.45e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDKN1A—lung cancer	3.7e-06	2.45e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APOA1—lung cancer	3.69e-06	2.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PTEN—lung cancer	3.69e-06	2.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MTOR—lung cancer	3.69e-06	2.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CB—lung cancer	3.69e-06	2.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CD4—lung cancer	3.68e-06	2.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL2—lung cancer	3.67e-06	2.43e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KDR—lung cancer	3.66e-06	2.42e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—lung cancer	3.66e-06	2.42e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT1—lung cancer	3.65e-06	2.42e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP2E1—lung cancer	3.61e-06	2.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CG—lung cancer	3.6e-06	2.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APC—lung cancer	3.6e-06	2.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KIT—lung cancer	3.6e-06	2.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—NRAS—lung cancer	3.6e-06	2.38e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—JUN—lung cancer	3.57e-06	2.36e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NQO1—lung cancer	3.57e-06	2.36e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGF—lung cancer	3.56e-06	2.36e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EP300—lung cancer	3.52e-06	2.33e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA3—lung cancer	3.49e-06	2.31e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—RRM1—lung cancer	3.49e-06	2.31e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	3.49e-06	2.31e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDKN1A—lung cancer	3.46e-06	2.29e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	3.46e-06	2.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTEN—lung cancer	3.45e-06	2.28e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—MAPK3—lung cancer	3.45e-06	2.28e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—POMC—lung cancer	3.43e-06	2.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—SRC—lung cancer	3.42e-06	2.26e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—lung cancer	3.42e-06	2.26e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1A—lung cancer	3.42e-06	2.26e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTEN—lung cancer	3.41e-06	2.25e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—BRAF—lung cancer	3.39e-06	2.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APC—lung cancer	3.37e-06	2.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KIT—lung cancer	3.37e-06	2.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CG—lung cancer	3.37e-06	2.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—NRAS—lung cancer	3.37e-06	2.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6R—lung cancer	3.35e-06	2.21e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CREBBP—lung cancer	3.34e-06	2.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGF—lung cancer	3.33e-06	2.2e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STAT3—lung cancer	3.3e-06	2.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EP300—lung cancer	3.29e-06	2.18e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NRAS—lung cancer	3.29e-06	2.18e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—B4GALT5—lung cancer	3.28e-06	2.17e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—lung cancer	3.28e-06	2.17e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EP300—lung cancer	3.25e-06	2.15e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—MAPK3—lung cancer	3.23e-06	2.14e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—STK11—lung cancer	3.21e-06	2.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—POMC—lung cancer	3.21e-06	2.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—SRC—lung cancer	3.2e-06	2.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1A—lung cancer	3.2e-06	2.11e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA4—lung cancer	3.2e-06	2.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAP2K1—lung cancer	3.19e-06	2.11e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTEN—lung cancer	3.19e-06	2.11e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—BRAF—lung cancer	3.17e-06	2.1e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CD—lung cancer	3.17e-06	2.1e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SRC—lung cancer	3.16e-06	2.09e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK3—lung cancer	3.15e-06	2.09e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6R—lung cancer	3.13e-06	2.07e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CREBBP—lung cancer	3.13e-06	2.07e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA2—lung cancer	3.11e-06	2.06e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—lung cancer	3.1e-06	2.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STAT3—lung cancer	3.09e-06	2.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NRAS—lung cancer	3.08e-06	2.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—lung cancer	3.07e-06	2.03e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STAT3—lung cancer	3.05e-06	2.02e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EP300—lung cancer	3.04e-06	2.01e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NRAS—lung cancer	3.04e-06	2.01e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.02e-06	2e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA1—lung cancer	3e-06	1.99e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—lung cancer	3e-06	1.98e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTP1—lung cancer	2.97e-06	1.97e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCC3—lung cancer	2.97e-06	1.96e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CD—lung cancer	2.96e-06	1.96e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SRC—lung cancer	2.96e-06	1.96e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK3—lung cancer	2.95e-06	1.95e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MAPK3—lung cancer	2.91e-06	1.93e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—lung cancer	2.9e-06	1.92e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CAT—lung cancer	2.89e-06	1.91e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.88e-06	1.9e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKR1C1—lung cancer	2.88e-06	1.9e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STAT3—lung cancer	2.85e-06	1.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CA—lung cancer	2.85e-06	1.88e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NRAS—lung cancer	2.84e-06	1.88e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MDM2—lung cancer	2.84e-06	1.88e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—lung cancer	2.83e-06	1.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—lung cancer	2.83e-06	1.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RAF1—lung cancer	2.83e-06	1.87e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ABCB1—lung cancer	2.82e-06	1.86e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—lung cancer	2.81e-06	1.86e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ERBB2—lung cancer	2.8e-06	1.85e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—UGT1A1—lung cancer	2.79e-06	1.85e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—lung cancer	2.77e-06	1.83e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TYMS—lung cancer	2.77e-06	1.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MTOR—lung cancer	2.76e-06	1.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CB—lung cancer	2.76e-06	1.83e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTM1—lung cancer	2.73e-06	1.81e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MAPK3—lung cancer	2.72e-06	1.8e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GNG11—lung cancer	2.69e-06	1.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CA—lung cancer	2.67e-06	1.76e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MDM2—lung cancer	2.66e-06	1.76e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL8—lung cancer	2.65e-06	1.76e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—lung cancer	2.65e-06	1.75e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—lung cancer	2.65e-06	1.75e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RAF1—lung cancer	2.65e-06	1.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRAS—lung cancer	2.64e-06	1.74e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ERBB2—lung cancer	2.62e-06	1.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—lung cancer	2.62e-06	1.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CA—lung cancer	2.6e-06	1.72e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—lung cancer	2.59e-06	1.71e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP1A1—lung cancer	2.59e-06	1.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CB—lung cancer	2.58e-06	1.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MTOR—lung cancer	2.58e-06	1.71e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ERCC2—lung cancer	2.57e-06	1.7e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALDOA—lung cancer	2.56e-06	1.7e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CASP3—lung cancer	2.54e-06	1.68e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL2—lung cancer	2.54e-06	1.68e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—lung cancer	2.52e-06	1.67e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NCOA3—lung cancer	2.49e-06	1.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL8—lung cancer	2.48e-06	1.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—lung cancer	2.47e-06	1.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—JUN—lung cancer	2.47e-06	1.63e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRAS—lung cancer	2.47e-06	1.63e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—lung cancer	2.45e-06	1.62e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CA—lung cancer	2.44e-06	1.61e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ADCY1—lung cancer	2.42e-06	1.6e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCG2—lung cancer	2.42e-06	1.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HRAS—lung cancer	2.41e-06	1.59e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CA—lung cancer	2.4e-06	1.59e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—lung cancer	2.4e-06	1.59e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1A—lung cancer	2.39e-06	1.58e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTEN—lung cancer	2.39e-06	1.58e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CASP3—lung cancer	2.38e-06	1.57e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HPGDS—lung cancer	2.37e-06	1.57e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ENO2—lung cancer	2.37e-06	1.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL2—lung cancer	2.37e-06	1.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—lung cancer	2.36e-06	1.56e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPP2R1B—lung cancer	2.36e-06	1.56e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—lung cancer	2.33e-06	1.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—lung cancer	2.31e-06	1.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—JUN—lung cancer	2.31e-06	1.53e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—lung cancer	2.31e-06	1.52e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTT1—lung cancer	2.3e-06	1.52e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GCLC—lung cancer	2.28e-06	1.51e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP2A6—lung cancer	2.28e-06	1.51e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EP300—lung cancer	2.28e-06	1.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HRAS—lung cancer	2.25e-06	1.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CA—lung cancer	2.25e-06	1.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—lung cancer	2.25e-06	1.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1A—lung cancer	2.24e-06	1.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTEN—lung cancer	2.23e-06	1.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HRAS—lung cancer	2.22e-06	1.47e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—APOA1—lung cancer	2.22e-06	1.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SRC—lung cancer	2.21e-06	1.46e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—lung cancer	2.18e-06	1.44e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ENO1—lung cancer	2.16e-06	1.43e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—lung cancer	2.16e-06	1.43e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—lung cancer	2.16e-06	1.43e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT3—lung cancer	2.13e-06	1.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EP300—lung cancer	2.13e-06	1.41e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NRAS—lung cancer	2.13e-06	1.41e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—lung cancer	2.13e-06	1.41e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.13e-06	1.41e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—lung cancer	2.13e-06	1.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HRAS—lung cancer	2.08e-06	1.38e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SRC—lung cancer	2.07e-06	1.37e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK3—lung cancer	2.04e-06	1.35e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CG—lung cancer	2.03e-06	1.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—lung cancer	2.02e-06	1.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STAT3—lung cancer	2e-06	1.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NRAS—lung cancer	1.99e-06	1.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—lung cancer	1.99e-06	1.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—lung cancer	1.99e-06	1.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—lung cancer	1.98e-06	1.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—lung cancer	1.96e-06	1.3e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—lung cancer	1.94e-06	1.28e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP2E1—lung cancer	1.94e-06	1.28e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—POMC—lung cancer	1.93e-06	1.28e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NQO1—lung cancer	1.91e-06	1.27e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK3—lung cancer	1.91e-06	1.26e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CREBBP—lung cancer	1.88e-06	1.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—lung cancer	1.86e-06	1.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—lung cancer	1.84e-06	1.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—lung cancer	1.83e-06	1.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—lung cancer	1.82e-06	1.2e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CD—lung cancer	1.78e-06	1.18e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALB—lung cancer	1.76e-06	1.16e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—STK11—lung cancer	1.73e-06	1.14e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—lung cancer	1.71e-06	1.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CA—lung cancer	1.68e-06	1.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—lung cancer	1.63e-06	1.08e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTP1—lung cancer	1.6e-06	1.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CA—lung cancer	1.58e-06	1.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRAS—lung cancer	1.56e-06	1.03e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CB—lung cancer	1.56e-06	1.03e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CAT—lung cancer	1.55e-06	1.03e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—lung cancer	1.54e-06	1.02e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—lung cancer	1.52e-06	1.01e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCB1—lung cancer	1.51e-06	9.99e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—lung cancer	1.49e-06	9.86e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TYMS—lung cancer	1.48e-06	9.81e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTM1—lung cancer	1.47e-06	9.7e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRAS—lung cancer	1.46e-06	9.64e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—lung cancer	1.39e-06	9.22e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP1A1—lung cancer	1.39e-06	9.2e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ERCC2—lung cancer	1.38e-06	9.12e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT1—lung cancer	1.38e-06	9.1e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTEN—lung cancer	1.34e-06	8.89e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—lung cancer	1.29e-06	8.51e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—EP300—lung cancer	1.28e-06	8.47e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—APOA1—lung cancer	1.19e-06	7.89e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CG—lung cancer	1.09e-06	7.2e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—POMC—lung cancer	1.04e-06	6.86e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CREBBP—lung cancer	1.01e-06	6.68e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CD—lung cancer	9.58e-07	6.33e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CA—lung cancer	9.48e-07	6.27e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALB—lung cancer	9.45e-07	6.25e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CB—lung cancer	8.35e-07	5.52e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—lung cancer	8.27e-07	5.47e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—lung cancer	7.74e-07	5.12e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTEN—lung cancer	7.21e-07	4.77e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—EP300—lung cancer	6.88e-07	4.55e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CA—lung cancer	5.09e-07	3.36e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—lung cancer	4.16e-07	2.75e-06	CbGpPWpGaD
